Research dossier
GHRP-6 — first-generation secretagogue dossier
A first-generation hexapeptide, the historical reference of the secretagogue family.
Translated from the French original, which remains the reference version: lire en français →
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 87616-84-0 |
| Molar mass | 873.01 g/mol |
| Molecular formula | C₄₆H₅₆N₁₂O₆ |
| Sequence / nature | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.
Research context
This compound has a precise historical value: it was used to characterise a receptor before its endogenous ligand was known. That reversed sequence — synthetic tool first, natural ligand second — is uncommon, and makes this peptide a methodological landmark in the field.
Mechanism studied
GHRP-6 is a hexapeptide agonist at GHSR-1a, belonging to the first generation of growth hormone secretagogue peptides. Its scientific interest is partly historical: it was one of the tools that established the existence of a receptor distinct from that of GHRH, before the endogenous ligand — ghrelin — was discovered.
That chronology is notable in pharmacology: the receptor was characterised by means of a synthetic ligand several years before its natural ligand was identified.
Like the other GHSR agonists, it activates the Gq/phospholipase C pathway with calcium mobilisation. Its selectivity is nonetheless lower than that of ipamorelin: published assays report residual activity on other pituitary axes, which makes it a useful comparator but a less specific tool for isolating the contribution of a single receptor.
In-vitro literature
The literature is long-standing and abundant. GHRP-6 frequently serves as a positive control in functional assays on GHSR-1a.
Bibliographic entry points
- PubMed — peer-reviewed literature
- PubChem — chemical profile and assay data
- NCBI — methodology and receptor references
These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.
Distinguishing this compound from its analogues
The first of the GHRP series. To be distinguished from GHRP-2 and hexarelin, of close sequence and different selectivity profiles.
The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.
Methodological limits
Lower selectivity than the later secretagogues: the residual activity reported on other pituitary axes is a confounding variable in any assay seeking to isolate the GHSR pathway. The tryptophan in the sequence is susceptible to oxidation, a measurable source of degradation.
These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.
Analytical parameters
A hexapeptide containing D residues and a tryptophan, the latter susceptible to oxidation. Storage away from light is justified by that sensitivity.
| Parameter | Value |
|---|---|
| Storage | Store at −20 °C, protected from light |
| Solubility | Soluble in bacteriostatic water (BAC) |
| Stability | Stable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C |
| Control methods | RP-HPLC · MS · NMR |
Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.
Resulting concentrations
The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.
| Format | 1 ml | 2 ml | 3 ml |
|---|---|---|---|
| 10mg | 10.00 mg/ml | 5.00 mg/ml | 3.33 mg/ml |
These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.
Protocol design
Three points govern the validity of an assay using this material, whatever the question being asked.
The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.
The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.
The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.
Lot verification
The following formats are covered by a Janoshik Analytical report, readable from the product page:
- 10mg — lot report available
| Format | Lot report | Availability |
|---|---|---|
| 10mg | Covered | In stock |
The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.
Frequently asked questions
How does this product arrive?
As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.
Which solvent should be used for reconstitution?
Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.
How long does the material remain stable?
The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.
Does the analysis report correspond exactly to my vial?
The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.
Can this product be used on humans or animals?
No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.
See also: CJC-1295, Ipamorelin, GHRP-6: GHRH and GHRP compared
Dossiers in the same category
- CJC-1295 (zonder DAC) — CAS 863288-34-0
- IGF-1 LR3 — CAS 946870-92-4
- Ipamorelin — CAS 170851-70-4